DrugId:  1
1. Name:  Riamet
2. Groups:  Approved, Investigational
3. Description:  Riamet has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria.
4. Indication:  Not Available
DrugId:  2
1. Name:  Mefloquine
2. Groups:  Approved, Investigational
3. Description:  A phospholipid-interacting antimalarial drug (antimalarials). It is very effective against plasmodium falciparum with very few side effects. [PubChem]
4. Indication:  For the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.
DrugId:  3
1. Name:  Sulfadoxine
2. Groups:  Approved, Investigational
3. Description:  A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. [PubChem]
4. Indication:  Sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria. It can also be used to treat various infections in livestock as well.Sulfadoxine and pyrimethamine is indicated for the treatment of Plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected. 
DrugId:  4
1. Name:  Artemisinin
2. Groups:  Investigational
3. Description:  Artemisinin has been used in trials studying the treatment of Schizophrenia, Malaria, Falciparum, and Plasmodium Falciparum.
4. Indication:  Not Available
DrugId:  5
1. Name:  Cipargamin
2. Groups:  Investigational
3. Description:  Cipargamin has been used in trials studying the treatment of Malaria, Cure Rate, and Plasmodium Falciparum Malaria.
4. Indication:  Not Available
DrugId:  6
1. Name:  Primaquine
2. Groups:  Approved
3. Description:  An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
4. Indication:  For the treatment of malaria.
DrugId:  7
1. Name:  Temefos
2. Groups:  Investigational
3. Description:  Diphos has been used in trials studying the treatment of Plasmodium Falciparum Malaria.
4. Indication:  Not Available
DrugId:  8
1. Name:  Proguanil
2. Groups:  Approved
3. Description:  Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, Plasmodium falciparum and Plasmodium vivax, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite.
4. Indication:  For the causal prevention and suppression of malaria caused by susceptible strains of P. falciparum and other species of Plasmodium found in some geographical areas of the world.
DrugId:  9
1. Name:  Artemether
2. Groups:  Approved
3. Description:  Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas. 
4. Indication:  Artemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg. 
DrugId:  10
1. Name:  Lumefantrine
2. Groups:  Approved
3. Description:  Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
4. Indication:  Lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg. 
DrugId:  11
1. Name:  Halofantrine
2. Groups:  Approved
3. Description:  Halofantrine is a drug used to treat malaria. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
4. Indication:  For treatment of Severe malaria
DrugId:  12
1. Name:  Artenimol
2. Groups:  Approved, Investigational
3. Description:  Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in combination with Piperaquine as the product Eurartesim. Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [12].
4. Indication:  For the treatment of uncomplicated Plasmodium falciparum infection in adults, children, and infants aged 6 months and up weighing over 5 kg [FDA Label]. Used in combination with Piperaquine.
DrugId:  13
1. Name:  Artesunate
2. Groups:  Approved, Investigational
3. Description:  Artesunate is part of the artemisinin group of drugs that treat malaria. It is a semi-synthetic derivative of artemisinin that is water-soluble and may therefore be given by injection. It is on the World Health Organization's List of Essential Medicines. It has been made available in the US under the investigational new drug protocol [2]. Artesunate is provided by the Centers for Disease Control and Prevention on an emergency basis.
4. Indication:  For the treatment of severe malaria caused by Plasmodium falciparum in adults and children [3]
DrugId:  14
1. Name:  Pyrimethamine
2. Groups:  Approved, Investigational, Vet approved
3. Description:  One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. [PubChem]
4. Indication:  For the treatment of toxoplasmosis and acute malaria; For the prevention of malaria in areas non-resistant to pyrimethamine
DrugId:  15
1. Name:  Doxycycline
2. Groups:  Approved, Investigational, Vet approved
3. Description:  A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum).
4. Indication:  Doxycycline is indicated for use in respiratory tract infections caused by Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Legionella spp., or Klebsiella spp. It is also used for prophylaxis of malaria. Doxycycline is indicated for a variety of bacterial infections, from Mycobacterium fortuitum and M. marinum, to susceptible E. coli and Brucella spp. It can be used as an alternative to treating plague, tetanus, Campylobacter fetus 
DrugId:  16
1. Name:  Quinine
2. Groups:  Approved
3. Description:  An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. [PubChem]
4. Indication:  For the treatment of malaria and leg cramps
DrugId:  17
1. Name:  Chloroquine
2. Groups:  Approved, Investigational, Vet approved
3. Description:  The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
4. Indication:  For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
DrugId:  18
1. Name:  PEV3A
2. Groups:  Investigational
3. Description:  PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimeticsPEV301 and PEV302. The two synthetic peptide vaccinecomponents mimic the native structure of important antigens of the malaria parasite. The elicitedantibodies are highly specific and able to inhibit the parasiteâ€™s ability to invade liver tissue invitro.
4. Indication:  Investigated for use/treatment in malaria.
DrugId:  19
1. Name:  Hydroxychloroquine
2. Groups:  Approved
3. Description:  A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites.
4. Indication:  For the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis.
DrugId:  20
1. Name:  Voacamine
2. Groups:  Approved, Investigational
3. Description:  Voacamine is an alkaloid isolated from the bark of the Pescheria fuchsiae folia tree. It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resistance in tumor cells. 
4. Indication:  For the treatment of malaria. Also under investigation for the modulation of multidrug resistance in cancer cells.
DrugId:  21
1. Name:  Tafenoquine
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in malaria.
DrugId:  22
1. Name:  p-Quaterphenyl
2. Groups:  Investigational
3. Description:  p-Quaterphenyl has been used in trials studying the treatment of Malaria.
4. Indication:  Not Available
DrugId:  23
1. Name:  Pafuramidine
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in pneumonia, trypanosomiasis, malaria, HIV infection, and infectious and parasitic disease (unspecified).
DrugId:  24
1. Name:  Artemotil
2. Groups:  Approved
3. Description:  Artemotil (INN; also known as Î²-arteether), is a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant Plasmodium falciparum malaria and cerebral malaria cases. It is a semi-synthetic derivative of artemisinin, a natural product of the Chinese plant Artemisia annua.
4. Indication:  Not Available
DrugId:  25
1. Name:  Piperaquine
2. Groups:  Approved, Investigational
3. Description:  Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China [1]. Its use declined in the 1980's as piperaquine resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became available. It has come back into use in combination with the artemisinin derivative Artenimol as part of the combination product Eurartesim [FDA Label]. Eurartesim was first authorized for market by the European Medicines Agency in October 2011.
4. Indication:  For the treatment of uncomplicated Plasmodium falciparum infection in adults, children, and infants aged 6 months and up weighing over 5 kg [FDA Label]. Used in combination with Artenimol.
